Klahn Shawna L, Kitchell Barbara E, Dervisis Nikolaos G
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, USA.
J Am Vet Med Assoc. 2011 Jul 1;239(1):90-6. doi: 10.2460/javma.239.1.90.
To evaluate and compare the outcomes of dogs with periarticular histiocytic sarcoma (PAHS) and histiocytic sarcoma of other anatomic locations (non-PAHS) and identify factors associated with outcome for dogs with PAHS.
Retrospective cohort study.
19 dogs with PAHS and 31 dogs with non-PAHS.
Medical records of dogs with histiocytic sarcoma that underwent definitive local treatment (surgery or radiation), chemotherapy, or a combination of these were reviewed. Patient signalment, clinical signs, staging test results, clinicopathologic data, type of treatment, response, and outcome were collected, and potential risk factors in dogs with PAHS were identified and analyzed for an association with outcome.
Dogs with PAHS lived significantly longer than did dogs with non-PAHS, with an overall median survival times of 391 (range, 48 to 980) and 128 (range, 14 to 918) days, respectively, despite the presence of suspected metastasis at diagnosis in 13 of 19 dogs with PAHS. Dogs with PAHS without evidence of metastasis at diagnosis lived significantly longer than did dogs with PAHS with evidence of metastasis, with median survival times of 980 (range, 83 to 980) and 253 (range, 48 to 441) days, respectively. Administration of prednisone in dogs with PAHS was associated with a significantly shorter time to tumor progression (TTP) and increased risk of tumor progression and death.
Results indicated that dogs with PAHS may have a favorable outcome independent of metastatic status when treated with chemotherapy or aggressive multimodal treatment. The concurrent administration of prednisone may be a negative predictive factor for survival time and TTP in dogs with PAHS.
评估并比较患有关节周围组织细胞肉瘤（PAHS）的犬与其他解剖部位组织细胞肉瘤（非PAHS）的预后情况，并确定与PAHS患犬预后相关的因素。
回顾性队列研究。
19只患有PAHS的犬和31只患有非PAHS的犬。
对接受了确定性局部治疗（手术或放疗）、化疗或两者联合治疗的组织细胞肉瘤患犬的病历进行回顾。收集患犬的信号、临床症状、分期检查结果、临床病理数据、治疗类型、反应和预后情况，并确定PAHS患犬的潜在风险因素并分析其与预后的关联。
尽管19只PAHS患犬中有13只在诊断时疑似有转移，但PAHS患犬的存活时间显著长于非PAHS患犬，总体中位生存时间分别为391天（范围48至980天）和128天（范围14至918天）。诊断时无转移证据的PAHS患犬的存活时间显著长于有转移证据的PAHS患犬，中位生存时间分别为980天（范围83至980天）和253天（范围48至441天）。PAHS患犬使用泼尼松与肿瘤进展时间（TTP）显著缩短以及肿瘤进展和死亡风险增加相关。
结果表明，PAHS患犬接受化疗或积极的多模式治疗时，可能有良好的预后，与转移状态无关。同时使用泼尼松可能是PAHS患犬生存时间和TTP的负面预测因素。
